Metformin and the sulfonylureas are the most heavily prescribed drugs in T2D and dominate the early lines of therapy prior to disease progression, which requires insulin replacement. The emergence of more-effective, safer, and/or better-tolerated therapies, such as the DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists, have provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of type 2 diabetes and its complications, individualized treatment for patients is becoming more commonplace. Numerous branded agents from both established and recently emergent classes are now jostling for position in the treatment paradigm.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
  • How have Jardiance, Trulicity, and Tresiba been integrated into the treatment algorithm?
  • What percentage of T2D patients receive drug therapy within one year of diagnosis? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most widely used combinations?
  • What are the compliance and persistency rates for T2D therapies?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.


Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Ozempic, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza


  • Brand use across a longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis in Type 2 Diabetes [February 2019]

Author(s): Shreya Saxena, MBA; Gideon Heap

Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.

As a Principal Analyst on the Cardiovascular, Metabolic and Renal Disorders team, Gideon has a wealth of experience and expertise in pharmaceutical market analysis. In addition to creating Disease Insights covering metabolic disorders, Gideon has experience in company strategy and portfolio analysis for DRG’s Company & Drug platform. Gideon has a Masters in Biochemistry with Biological Chemistry from the University of Nottingham, and his industry experience dates back to 2009.

Related Reports

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the d...

View Details

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis: Injectables (US/EU)

The type 2 diabetes (T2D) therapy market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details

Type 2 Diabetes | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patien...

View Details